由mirabegron诱导的膀光滑肌细胞中的动态表型变化和M2受体下调
A E Muderrisoglu1,2, A Ciotkowska1, B Rutz1
1Department of Urology, LMU University Hospital, LMU Munich, Munich, Germany.
Frontiers in pharmacology
|August 8, 2024
概括
米拉贝格朗改变了人体膀光滑肌肉细胞表型和M2受体表达,可能通过时间转移的抗收缩作用改善过度活跃膀 (OAB) 症状.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 使用mirabegron治疗过度活跃的膀 (OAB) 缺乏对其机制和对膀光滑肌细胞的长期影响的明确理解.
- 膀光滑肌的收缩性和生长是OAB的关键因素,受细胞表型和肌肉蛋白受体表达的影响.
研究的目的:
- 为了研究长时间暴露于mirabegron对人类膀光滑肌细胞 (hBSMC) 的影响.
- 为了检查hBSMC表型标记物的变化,肌肉蛋白受体表达和mirabegron治疗后的功能.
主要方法:
- 人类膀光滑肌细胞 (hBSMC) 暴露于mirabegron20-48小时.
- 用RT-PCR分析了表型标记物 (calponin,MYH11,MYH10,vimentin) 和肌酸受体的基因表达.
- 用EDU,CCK-8,phalloidin染色和矩阵收缩试验来评估细胞增殖,活力,行为组织和收缩性.
主要成果:
- 米拉贝格隆改变了收缩和增殖标记的mRNA表达,其中一些影响是时间依赖的,对β3-AR抗剂有部分敏感.
- 细胞活力随着mirabegron暴露而增加,这种效应对抗剂敏感,而增殖和actin组织保持稳定.
- 米拉贝格隆降低了M2 mRNA的表达,并抑制了晚期的,但不是早期的,卡巴霍尔诱导的hBSMC收缩.
结论:
- 米拉贝格朗诱导hBSMC中的动态表型变化和M2受体下调.
- 这些细胞变化伴随着时间转移的抗收缩效应.
- 在hBSMC中的表型转换可能有助于mirabegron在OAB储存症状中的治疗益处.
相关概念视频
The Micturition Reflex
523
Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
523
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K
Cholinergic Antagonists: Pharmacological Actions
1.0K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.0K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
233
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
233
Cholinergic Antagonists: Therapeutic Uses
733
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
733
Cholinergic Antagonists: Pharmacokinetics
425
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
425


